67367-39-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(Chloromethyl)-2-methoxynaphthalene is used as an intermediate for the production of pharmaceuticals. Its unique structure allows for the creation of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(Chloromethyl)-2-methoxynaphthalene is utilized as an intermediate in the synthesis of various agrochemicals. Its application aids in the development of products that enhance crop protection and contribute to sustainable agricultural practices.
Used in Organic Synthesis:
1-(Chloromethyl)-2-methoxynaphthalene is also employed in the synthesis of different organic compounds. Its naphthalene and chloromethyl groups provide a foundation for creating a diverse array of organic molecules for various applications, including materials science and specialty chemicals.
Precaution:
Due to its potential health hazards, 1-(Chloromethyl)-2-methoxynaphthalene should be handled with care in a controlled environment to ensure safety and minimize risks.

Upstream product

• 40696-22-8 (2-methoxy-naphthalene-1-yl)-methanol 
• 93-04-9 2-Methoxynaphthalene 
• 5392-12-1 2-methoxy-1-naphthaldehyde 
• 136402-93-2 1-aminomethyl-2-methoxynaphthalene 
• 50-00-0 formaldehyd 

Downstream Products

• 1421365-46-9 C₂₃H₁₉ClN₂O₄ 
• 1442483-02-4 2-((2-methoxynaphthalen-1-yl)methyl)-2-(1-phenylbut-3-en-1-yl)malononitrile 
• 1130-80-9 2-methoxy-1-methylnaphthalene 
• 40696-22-8 (2-methoxy-naphthalene-1-yl)-methanol 

Relevant academic research and scientific papers

Palladium-catalyzed amination of chloromethylnaphthalene and chloromethylanthracene derivatives with various amines

Palladium-catalyzed amination of chloromethylnaphthalene and chloromethylanthracene derivatives to produce naphthylamines and anthrylamines in satisfactory to good yields has been developed. The unprecedented amination reactions proceeded smoothly under mild conditions in the presence of Pd(PPh3)4 as a catalyst.

TRICYCLIC AMIDES

The invention relates to a compound selected from these of formula (I) : STR1 in which R 7, R 8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

O-arylmethyl-N-(thio)acylhydroxylamines

The invention relates to a compound selected from those of formula (I): STR1 in which Ar, X, R 1 and R 2 are as defined in the description and a medicinal product containing the same in order to treat a disorder of the melatoninergic system.

Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors

Tetrahydroanthracene, tetrahydrophenanthrene, and tetrahydrophenalene moieties were used to design novel constrained melatoninergic agents. Compounds 1 and 2 were synthesized from the cyclization of the aryl succinic acids 6a,b followed by catalytic reduction, Curtius degradation to the amino derivatives, and acetylation. The phenalene derivatives 3 were prepared by cyclization of the aza lactones of the corresponding α-N-acetyl amino acids. The ketone derivatives were reduced directly by catalytic hydrogenation to produce the compounds 3. The different compounds were evaluated in vitro in binding assays using 2-[125I]iodomelatonin and chicken brain membranes. Melatonin and 2-acetamido-8-methoxytetralin were used as the reference compounds. The results showed the superiority of the dihydrophenalene framework 3 over those of tetrahydroanthracene and tetrahydrophenanthrene. 3a had relatively good affinity for melatonin receptors (K(i) = 28.7 nM). Introduction of an additional methoxy group gave a derivative (3c) with nanomolar affinity (K(i) = 0.7 nM), confirming the existence of a secondary binding site in the receptor which has been described previously. An increase in the affinity was also observed with the propionamido derivative 3e (K(i) = 6.0 nM). The potential agonist properties of the compound 3e were evaluated on the dermal melanocytes of Xenopus laevis tadpoles. At the concentration of 2.3 nM (5 x K(i)), melatonin gave a melanophore index value of 1. Similarly to melatonin, 3e was shown to be a potent agonist of the melanosome aggregation.